Objectives This open-label, randomized phase II trial evaluated antitumor efficacy of an
antiestrogen, fulvestrant, in combination with human epidermal growth factor receptor …

Background: EGFR inhibition is an established therapy for previously treated NSCLC.
Estrogen receptors (ER) and aromatase are expressed in most NSCLC specimens in both …

Introduction Estrogen receptor (ER) signaling and its interaction with epidermal growth factor
receptor (EGFR) is a potential therapeutic target in non–small-cell lung cancer (NSCLC). To …

INTRODUCTION: Estrogen receptor beta (ERβ) has been detected in non-small cell lung
cancer (NSCLC) cell lines and tumor specimens. The ER down-regulator, fulvestrant …

Importance Erlotinib is a standard first-line therapy for patients with epidermal growth factor
receptor (EGFR)–mutant non–small cell lung cancer (NSCLC). Median progression-free …

Erlotinib is an orally administered small molecule inhibitor of epidermal growth factor
receptor (EGFR) tyrosine kinase. Erlotinib at the standard oral daily dose of 150 mg is …

BACKGROUND Erlotinib is a standard first‐line therapy for patients who have metastatic
nonsmall cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations …

Lung cancer is the leading cause of cancer deaths worldwide. Targeting the epidermal
growth factor receptor (EGFR) has played a central role in advancing non-small-cell lung …

Erlotinib is a relatively well-tolerated treatment option for patients with advanced non-small-
cell lung cancer (NSCLC). Some patients suffer from severe skin toxicity or diarrhea, making …

Approximately 213,380 new cases of non-small-cell lung cancer (NSCLC) were estimated to
occur in the USA in 2007, which caused 160,390 NSCLC-related deaths. The majority of …